Organisation paid for research Program year 2021 Source: CMS Open Payments

Premier Urology Group LLC

Neither a doctor nor a teaching hospital

Research payments

$404,005

45 payments

Through program year 2021, Premier Urology Group LLC is reported as receiving $404,005 in research payments, across 45 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$80,864	12
2020	Research	$86,007	15
2019	Research	$237,133	18

Breakdown

Who paid Research payments · program years 2019–2021

Allergan Inc. $393,812 40 payments
Spectrum Pharmaceuticals Inc. $10,130 3 payments
Urovant Sciences Inc $63 2 payments

Studies the money was for Research payments · program years 2019–2021

A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $152,097 10 payments
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Treatment, 2-Stage, Dose Finding Study Evaluating the Efficacy and Safety of Botox Intravesical Installation in Participants With Overactive Bladder and Urinary Incontinence. $89,960 8 payments
Androderm 24-Hr ABPM $75,933 8 payments
Androderm 24-Hr ABPM $67,354 10 payments
Spi-Qap-306 $10,130 3 payments
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $4,735 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate An Enhanced Injection Paradigm for Onabotulinumtoxina Botox in the Treatment of Overactive Bladder in Patients With Urinary Incontinence $3,599 2 payments
A Phase IV, Multi-Center, Open-Label, Single-Arm 24-Hour Ambulatory Blood Pressure Monitoring (Abpm) Study of 16 Weeks Treatment With Androderm in Hypogonadal Men $133 1 payment
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $63 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.